4/A: Pacira BioSciences Director Marcelo Bigal Amends Form 4 Filing to Correct Typographical Error
SEC Filing
Marcelo Bigal, a director of Pacira BioSciences, filed an amended Form 4 to correct a typographical error in the original filing related to share purchases.
Summary
- Marcelo Bigal, a director at Pacira BioSciences, filed an amended Form 4 with the SEC.
- The amendment corrects a typographical error in Footnote 1 of the original Form 4, which incorrectly referenced shares being sold instead of purchased.
- The original transaction date was August 12, 2024, and the amended filing is dated August 13, 2024.
- On August 12, 2024, Bigal purchased 3,400 shares of Pacira BioSciences common stock at a weighted average price of $12.01.
- The prices for these shares ranged from $11.75 to $12.35.
- Following the reported transaction, Bigal beneficially owns 8,630 shares of Pacira BioSciences common stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing. The correction of a typographical error is a neutral event.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, such as directors, and are required by the SEC to ensure transparency and prevent insider trading.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Original transaction date: Purchase of 3,400 shares of Pacira BioSciences common stock. |
| 08/12/2024 | Date of original Form 4 filing. |
| 08/13/2024 | Date of amended Form 4 filing to correct typographical errors. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.